Savient Pharmaceuticals, Inc.'s Puricase(R) Phase 2 Results Show Powerful Anti-Hyperuricemic Activity In Treatment-Failure Gout Patients

EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--June 22, 2006--Savient Pharmaceuticals, Inc. (NASDAQ:SVNT - News) today presented additional Phase 2 results for its Phase 3 compound Puricase® (PEG-uricase) at the European League Against Rheumatism (EULAR) 2006 Annual Congress in Amsterdam. The new data extended upon the abstracts shown at the American College of Rheumatology (ACR) meeting in November 2005. Puricase (PEG-uricase) is being developed for the control of hyperurecemia in treatment-failure gout.

Back to news